PharVision Advisers’s Guardant Health GH Stock Holding History

PharVision Advisers’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,366	Closed	-$273K	–	808
2025 Q3	$273K	Buy	+4,366	New	+$238K	0.15%	285

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PharVision Advisers's GH Position: Q4 2025 in Review

PharVision Advisers sold out of Guardant Health (GH) in Q4 2025, closing a stake of 4,366 shares — an estimated $273K sold.

PharVision Advisers first reported a position in GH in Q3 2025 and held it in 1 quarter. The position peaked at $273K in Q3 2025. 496 funds tracked by Wall St. Rank hold GH as of Q4 2025.

PharVision Advisers reported no remaining Guardant Health position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 4,366 Guardant Health shares in Q4 2025, an estimated $273K.
PharVision Advisers first reported a position in Guardant Health in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Guardant Health position peaked at $273K in Q3 2025.
496 funds tracked by Wall St. Rank held Guardant Health as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.